First-line treatment of NLPHL with HL-directed approaches
Dennis Eichenauer
09:55–10:15
Treatment of NLPHL with NHL-directed approaches
Graham Collins
10:30 – 12:00
Room: Großer Saal
Scientific SessionLiving Beyond Lymphoma
John Radford
Flora van Leeuwen
10:30–10:50
Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)
Stephen Ansell
10:50–11:10
Starting Living beyond Lymphoma with HL diagnosis
Karolin Behringer
Maximilian Büttner
11:10–11:30
Participation in and (cost-)effectiveness of the Dutch HL survivorship care program
Berthe Aleman
Annelies Nijdam
Abstract Talk
A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations
Michael Oertel
Abstract Talk
Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
Sidsel Juul
Abstract Talk
Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors
Zeinab Salah Seliem
12:30 – 14:00
Room: Großer Saal
Scientific SessionRelapsed & Refractory HL
Philippe Armand
Craig H. Moskowitz
12:30–12:50
Updated approach to second-line treatment
Alison Moskowitz
12:50–13:10
Emerging strategies to overcome anti-PD1 resistance
Stephen Ansell
13:10–13:30
Implementing raditoherapeutic concepts in rrHL care
Christian Baues
Abstract Talk
Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.
Anna Sureda
Abstract Talk
Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients
Francesco Corrado
Abstract Talk
Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin